Can thrombosis of six segmental pulmonary arteries cause pulmonary hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Yes, thrombosis of six segmental pulmonary arteries can absolutely cause pulmonary hypertension.

Chronic thrombotic obstruction at the segmental level is a well-recognized cause of chronic thromboembolic pulmonary hypertension (CTEPH), classified as Group 6 pulmonary hypertension according to the ESC/ERS guidelines 1, 2.

Pathophysiologic Mechanism

The development of pulmonary hypertension from segmental artery thrombosis follows this pathway:

  • Initial thrombotic obstruction: When thrombi fail to resolve after acute pulmonary embolism, they become incorporated into the vessel wall at the main, lobar, segmental, or subsegmental levels 2, 3
  • Vascular remodeling: Over time, the embolic material transforms into fibrous and elastic tissue, creating bands, webs, and chronic obstruction 3
  • Secondary small-vessel vasculopathy: Critically, chronic obstruction triggers a pulmonary microvascular arteriopathy in non-obstructed vessels, resembling idiopathic pulmonary arterial hypertension 3
  • Hemodynamic consequence: Pulmonary hypertension develops when the remaining vascular bed cannot accommodate cardiac output, either from the degree of proximal obstruction alone or combined with secondary small-vessel disease 3

Clinical Classification and Diagnostic Criteria

CTEPH is definitively diagnosed when pre-capillary pulmonary hypertension (mean PAP ≥25 mmHg, PCWP ≤15 mmHg, PVR >3 Wood units) occurs with multiple chronic/organized occlusive thrombi/emboli in the elastic pulmonary arteries, including segmental and subsegmental vessels 2.

The surgical classification system specifically recognizes segmental disease:

  • Type 3 disease (30% of CTEPH cases): Fibrosis, intimal webbing, and thickening within distal segmental and subsegmental arteries only 3
  • This represents the most challenging surgical scenario but confirms that segmental-level disease alone can cause clinically significant pulmonary hypertension

Critical Clinical Considerations

Extent of Obstruction Matters

Six segmental arteries represent substantial vascular territory. The pulmonary arterial tree has approximately 10 segmental arteries per lung (20 total), so obstruction of 6 segments represents roughly 30% of the segmental circulation—sufficient to cause hemodynamic compromise, particularly when combined with secondary microvascular remodeling 3.

The "Mismatch" Phenomenon

There is often poor correlation between the degree of angiographic obstruction and pulmonary arterial pressure elevation 3. This occurs because:

  • Secondary small-vessel arteriopathy contributes significantly to elevated pulmonary vascular resistance
  • Total PVR in CTEPH patients exceeds that of acute PE patients with similar proximal obstruction
  • Pulmonary hypertension can progress even without recurrent thromboembolism 3

Diagnostic Pitfall

Do not assume segmental-level disease is "too distal" to cause pulmonary hypertension. The guidelines explicitly include segmental and subsegmental vessels in the CTEPH definition 2, and the surgical classification confirms that isolated segmental disease (Type 3) causes pulmonary hypertension requiring treatment 3.

Management Implications

All patients with unexplained pulmonary hypertension should be evaluated for CTEPH, regardless of whether thrombi are at the main, lobar, or segmental level 2:

  • Ventilation/perfusion scanning is the screening test of choice
  • Multi-row CT angiography follows if V/Q shows perfusion defects
  • Referral to an expert CTEPH center is mandatory once imaging suggests chronic thromboembolic disease 2
  • Right heart catheterization and pulmonary angiography confirm diagnosis and guide treatment
  • Lifelong anticoagulation is indicated 2

Treatment options depend on location and extent:

  • Pulmonary endarterectomy remains first-line for accessible disease
  • Balloon pulmonary angioplasty for segmental/subsegmental disease 4, 5
  • Pulmonary hypertension-specific medical therapy for inoperable patients or residual PH 2, 5

The bottom line: Six segmental artery thromboses represent sufficient vascular obstruction to cause CTEPH, particularly when combined with the inevitable secondary microvascular remodeling that accompanies chronic thromboembolic obstruction.

Related Questions

What are the treatment options for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)?
Are beta‑blockers safe or appropriate for patients with pulmonary hypertension, and when can they be used?
How should a 7-year-old child with a fever of 103.3 °F and a productive cough be evaluated and managed?
How should I evaluate and manage a patient with a blood pressure of 122/77 mm Hg and a heart rate of 123 beats per minute (tachycardia)?
How should I assess and treat an 11-year-old girl with two months of persistent abdominal pain?
What is the diagnostic approach for post‑viral tussive syndrome?
Should a patient with acute small‑bowel infarction and pancolitis be kept NPO (nothing by mouth) and placed on bowel rest?
Is tramadol appropriate for postoperative analgesia in a patient with an active generalized rash of unknown cause who is already receiving scheduled intravenous acetaminophen and a TAP block, with breakthrough pain despite opioid rescue?
What family planning method is recommended for a patient undergoing HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol) therapy?
In a patient with compensated cirrhosis, type 2 diabetes, normal prothrombin time/international normalized ratio (PT/INR), and liver dysfunction primarily due to hepatic congestion from mitral valve disease, does the absence of esophageal varices change the risk‑benefit assessment for choosing a mechanical versus a bioprosthetic mitral valve?
In a patient with stage IV chronic kidney disease (estimated GFR ~19 mL/min/1.73 m²), can an angiotensin‑II receptor blocker (sartan) be prescribed for hypertension, and is doxazosin also appropriate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.